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Hematological cancerNatural killer (NK) cells, a cytotoxic lymphocyte lineage, are able to kill tumor cells in vitro and inmousemodels.
However, whether these cells display an anti-tumor activity in cancer patients has not been demonstrated. Here
we have addressed this issue in patients with several hematological cancers. We found a population of highly
activated CD56dimCD16+ NK cells that have recently degranulated, evidence of killing activity, and it is absent
in healthy donors. A high percentage of these cells expressed natural killer cell p46-related protein (NKp46),
natural-killer group 2,memberD (NKG2D) and killer inhibitory receptors (KIRs) and a lowpercentage expressed
NKG2A and CD94. They are also characterized by a high metabolic activity and active proliferation. Notably, we
found that activated NK cells from hematological cancer patients have non-NK tumor cell antigens on their
surface, evidence of trogocytosis during tumor cell killing. Finally, we found that these activated NK cells are dis-
tinguished by their CD45RA+RO+ phenotype, as opposed to non-activated cells in patients or in healthy donors
displaying a CD45RA+RO− phenotype similar to naïve T cells. In summary, we show that CD45RA+RO+ cells,
which resemble a unique NK population, have recognized tumor cells and degranulate in patients with hemato-
logical neoplasias.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The immune system recognizes and eliminates tumor cells (Dunn
et al., 2002), which defend themselves by different mechanisms
(Villalba et al., 2013). The lymphocyte lineage natural killer (NK) cell be-
longs to the innate immune system (Lanier, 2008; Vivier et al., 2008)
and show strong anti-leukemia activity when engrafted in allogeneic
settings in hematological cancer patients (Velardi, 2008; Ruggeri et al.,
2007; Anel et al., 2012). However, the presence of an anti-leukemia
NK cell population in patients with hematological malignancies has
not been proven.
NK cells are not a homogenous population and different subsets
have different physiological activities. Moreover, different stimuli
(e.g., cytokines vs targets cells) give rise to different immunophenotypesde Regenerative Medicine and
er Cedex 5, France.
.
. This is an open access article under(Fujisaki et al., 2009; Sanchez-Martinez et al., 2014). In peripheral blood,
human NK cells are mostly CD3−CD56dim cells with high cytotoxic activ-
ity, while CD3−CD56brigth cells excel in cytokine production (Bryceson
et al., 2011). In vitro evidence indicates that CD56bright NK cells are precur-
sors of CD56dim NK cells and this might also be the case in vivo (Domaica
et al., 2012). In addition, combined analysis of CD56 and CD16 expression
during NK cell development indicates that their proﬁles change as
follows: CD56brigthCD16− → CD56brigthCD16dim → CD56dimCD16dim →
CD56dimCD16+. Additional markers can be used to identify speciﬁc sub-
sets within these NK cell populations (Moretta, 2010; Freud et al., 2014).
Identiﬁcation of antileukemic NK cells in vivo is complex. CD69
expression increases after NK cell activation but it is not exclusive of
NK cells encountering tumor cells (Fogel et al., 2013; Elpek et al.,
2010). Due to the clinical interest of NK cells, it is therefore highly rele-
vant to identifymore precisely theNK cell population(s)with antitumor
functions.
CD45 is a protein tyrosine phosphatase that is speciﬁcally expressed
in leucocytes (Kaplan et al., 1990). CD45 regulates receptor signaling bythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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phosphorylating and activating various Src family kinases (SFK) (Rhee
and Veillette, 2012). However, it can also hinder cytokine receptor sig-
naling by inhibiting Janus kinases (JAK) (Irie-Sasaki et al., 2001) or by
dephosphorylating Src activating residues (Rhee and Veillette, 2012).
CD45 activity is critical for efﬁcient immune response, because its deﬁ-
ciency results in severe combined immunodeﬁciency (SCID) in mice
(Kishihara et al., 1993; Byth et al., 1996; Mee et al., 1999) and humans
(Kung et al., 2000; Tchilian et al., 2001).
Total CD45 expression increases with T cell maturation (Hermiston
et al., 2009), but the CD45 family comprises several isoforms derived
from a single complex gene (Hermiston et al., 2009). Naive T lympho-
cytes usually express the long CD45RA isoform. Activated and memory
T cells express CD45RO, the shortest CD45 isoform, generated by
activation-induced alternative splicing of CD45 pre-mRNA (Warren
and Skipsey, 1991; Roth, 1994; Lynch and Weiss, 2000; Hermiston
et al., 2009). It has been proposed that CD45RO expression also iden-
tiﬁes memory NK cells (Fu et al., 2011). Little is known about CD45 ex-
pression and function in NK cells, although it is commonly accepted that
CD45 positively regulates their activation by dephosphorylating the in-
hibitory site of SFKs, thus leading to cytokine and chemokine produc-
tion. However, in vitro cytotoxicity is only slightly impaired in NK cells
derived from CD45-deﬁcient mice (Huntington et al., 2005; Hesslein
et al., 2006;Mason et al., 2006). Asmost of what is knownwas obtained
inmousemodels and cannot be transposed to humans, the role of CD45
in human NK cells is an open issue and could depend on the type and
strength of the activation.
Here we show that, in contrast to T cells, NK cells can express both
CD45 isoforms: CD45RA and CD45RO. Moreover, these CD45RARO NK
cells recognize tumor cells in patients with hematological cancers and,
subsequently, degranulate.
1.1. Experimental Procedures
1.1.1. Cell Culture
The K562 cell line (ATCC CCL 243) and the lymphoblastoid EBV cell
line PLH (IHW Number: 9047) were maintained in logarithmic growth
in RPMI 1640 medium (Gibco® GlutaMAX™media) with 10% fetal bo-
vine serum (FBS) (Gibco®). Cells were cultured at 37 °C in a humidiﬁed
chamber with 5% CO2 in air, and passaged 1:10 twice a week.
1.1.2. Peripheral Blood Mononuclear Cell (PBMC) Puriﬁcation
Bonemarrow and peripheral blood samples were obtained from pa-
tients with different hematological diseases and from healthy donors
after informed consent. Cells were puriﬁed by Ficoll-Hypaque (Sigma)
density-gradient centrifugation as described earlier (Allende-Vega
et al., 2015). Brieﬂy, 3–6ml of 1:2 diluted blood or 1:3 diluted bonemar-
row samples in RPMI were added on top of 5 ml of Histopaque. Cells
were centrifuged at 1600 rpm and at 20 °C without break for 30 min.
Mononuclear cells were collected from the interlayer white ring. After
washing in RPMI, cells were suspended in complete RPMI medium sup-
plemented with 10% FBS (Invitrogen).
1.1.3. In Vitro NK Cell Stimulation Protocol
PBMCs, 1.106 cells/ml, were stimulated during 10 or 20 days with a
high dose of IL-2 (1000 U/ml, eBiosciences) or with the lymphoblastoid
EBV cell line PLH together with IL-2 (100 U/ml) and IL-15 (5 ng/ml,
Miltenyi).
1.1.4. Selection of Patients and Healthy Donors
Data and samples from patients with different hematological can-
cers were collected at the Oncology and Clinical Hematology Depart-
ment of the CHU Montpellier, France, after patient's informed consent
(Allende-Vega et al., 2015). Patients were enrolled in two independent
clinical programs approved by the “Comités de Protection des
Personnes Sud Méditerranée I”: ref 1324 and ID-RCB: 2011-A00924-37. All samples from cancer patients were collected at diagnosis and in-
cluded HD, Healthy donor (nbs = 10);MM, multiple myeloma (nbs =
19, nbms = 20); B-CLL, B-cell chronic lymphocytic leukemia (nbs =
15); BCL, B-cell lymphoma (nbs = 14); AML, acute myeloid leukemia
(nbs = 14); bs, blood samples; bms, bone marrow samples.
1.1.5. Multicolor Staining of Cell Surface Markers
PBMCs were stained with 7AAD (Beckman) to identify viable
cells and with the following anti-CD25-FITC,−CD45RO-FITC,−CD161-
FITC, −CD3-PE, −CD19-PE, −CD62L-PE, −CD69-PE, −CD138-PE,
−CD314(NKG2D)-PE, −CD3-ECD, −CD19-ECD, −CD38-ECD,
−CD56-PECy7, CD3-APC, −CD56-APC, −GzB-AlexaFluor700,
−CD19-AlexaFluor700, −CD20-APC-AlexaFluor750, −CD45-APC-
AlexaFluor750, −CD45RA-APC-AlexaFluor750, −CD5-PaciﬁcBlue,
−CD16-PaciﬁcBlue,−CD57-PaciﬁcBlue,−CD45-KromeOrange,−CD16-
KromeOrange (Beckman), −CD158b-FITC, −CD158a-PE, −CD107a-
HV500,−Ki-67-V450 (BD Biosciences),−CD45RA-FITC,−CD45RO-PE,
−CD159a(NKG2A)-PE, −CD335(NKp46)-PE, −CD94-PE-Vio770,
−CD335(NKp46)-PE-Vio770,−CD45RO-APC,−CD14-VioBlue,−CD19-
VioBlue,−CD158e-VioBlue (Miltenyi Biotec) and -CD71-APC (Immuno-
Tools) antibodies against surface markers for cell phenotyping. Brieﬂy,
1x106 cells were incubated with the different antibodies in PBS with 2%
FBS at 37 °C for 30 min. Cells were then washed and suspended in
200–250 μl PBS 2% FBS and staining was analyzed using a Gallios ﬂow
cytometer (Beckman) and the Kaluza software.
Viable lymphocytes were gated using FSC-SSC and 7AAD staining. B
lymphocytes (CD19+), T lymphocytes (CD3+CD56−) and NK cells
(CD56+CD3−) were differentiated based on CD19, CD3 or CD56 expres-
sion. NK cells were then separated in four distinct populations based on
CD45RA and CD45RO expression: CD45RA+RO− (CD45RA), CD45RA+-
RO+ (CD45RARO), CD45RAdimRO− (CD45RAdim), CD45RAdimRO+
(CD45RAdimRO). These different populations were then analyzed for
CD16, CD57, CD62L, CD69, CD71, CD94, CD107a, CD158a, CD158b,
CD158e, CD159a (NKG2A), CD161, CD314 (NKG2D), CD335 (NKp46),
Ki-67, GzB expression and cell size and granularity (FSC and SSC).
1.1.6. In Vitro CD107a Degranulation Assay
After PBMC puriﬁcation and NK cell quantiﬁcation, 3 million cells
were incubated at 37 °C for 4 h or overnight with K562 target cells at
an Effector (NK cell): Target ratio of 1:10 in a ﬁnal volume of 500 μl
(RPMI Glutamax with 10% FBS and 10U/ml IL2). The medium also
contained 1.5 μl anti-CD107a antibody (BD Biosciences, Franklin Lakes,
NJ) and 1 μl monensin to prevent CD107a degradation (BD Golgi-Stop
BD Biosciences). Then, cells were resuspended in 50 μl of an antibody
cocktail containing the anti-CD45RO-FITC, −CD69-PE, −CD19-ECD,
−7AAD, −CD56-PECy7, −CD3-APC, −CD45RA-APCAlexaFluor750,
−CD107a-HV500 and −CD16-KO antibodies (BD Biosciences,
Beckman). Samples were analyzed on a Beckman Coulter FACS Gallios
ﬂow cytometer using the Kaluza software. Events were initially gated
on forward and side scatter (SSC) to identify lymphocytes. A bivariate
plot of CD56 versus CD3 was used to acquire at least 10,000 NK cells.
1.1.7. Multicolor Staining for Cell Surface and Intracellular Markers
After PBMC puriﬁcation, 1 million cells were pre-blocked by incuba-
tion with 10% normal human serum at RT for 15 min and then stained
with 50 μl of the PANEL Ki-67 antibody cocktail against cell surface
markers (anti-CD45RO-PE, −CD19-ECD, −CD56-PC7, −CD3-APC,
−CD45RA-APCAlexaFluor750 and−CD16-KO antibodies) (BD Biosci-
ences, Beckman). Cells were washed twice with Staining Buffer and re-
suspended in 250 μl BD Cytoﬁx-Cytoperm solution at 4 °C for 20 min.
Cells were washed twice in BD Perm-Wash solution. Next, cells were
ﬁxed-permeabilized in 50 μl BD Perm-Wash solution containing an an-
tibody cocktail against intracellular markers (anti-GzB-AlexaFluor700,
−Ki-67-V450) as described in the ﬁgures at 4 °C for 30 min in the
dark. Cells were washed twice in BD Perm-Wash solution and resus-
pended in Staining Buffer prior to ﬂow cytometric analysis on a
1366 E. Krzywinska et al. / EBioMedicine 2 (2015) 1364–1376Beckman Coulter FACS Gallios ﬂow cytometer using the Kaluza soft-
ware. Events were initially gated on forward and side scatter (SSC) to
identify lymphocytes. A bivariate plot of CD56 versus CD3 was used to
acquire at least 10,000 NK cells.
1.1.8. Identiﬁcation of Pure Single NK Cells
Primary CD56+ NK cells were enriched and puriﬁed from PBMCs of
B-cell lymphomapatientswith the CD56+NK cell isolation kit (Miltenyi
Biotec, Auburn, CA, USA). The purity (% of CD56+CD3−) of CD56+ NK
cells, measured by ﬂow cytometry, was N90%. Puriﬁed CD56+ NK cells
have been stained with anti-CD335(NKp46)-PE to formally identify NK
cells together with anti-CD45RA-FITC, −CD45RO-APC and −CD19-
VioBlue (detection of trogocytosis-capable NK cells). Puriﬁed and stained
NK cells have been analyzed with the DEPArray™ System (Silicon
Biosystems, Menarini). This technology allowed us to detect, enu-
merate and take pictures of single cells.
1.1.9. DEPArrayTM Procedure
Cell sorting experiments were performed as described in the manu-
facturer's instructions and in (Lianidou et al., 2013). Brieﬂy, DEPArray car-
tridgesweremanually loadedwith 14 μl of sample and800 μl of the buffer
solution in which puriﬁed and stained NK cells had to be recovered. After
loading the cartridge into the DEPArray system, ∼9.26 μl of sample was
automatically injected by the system into amicrochamber of the cartridge
where the cells were spontaneously organized into a preprogrammed
electric ﬁeld consisting of 16,000 electrical cages in which individual
cells are trapped. Image frames covering the entire surface area of the
microchamber for each of four ﬂuorescent ﬁlter cubes (FITC, PE, APC
andDAPI-Hoechst-VioBlue-PaciﬁcBlue) andbrightﬁeld imageswere cap-
tured. Captured images were digitally processed and presented in a soft-
ware module that enables selection of cells of interest by the operator.
1.1.10. Statistics
All the experiments shown in the ﬁgures were performed at least
with samples from six patients for eachmalignancy and the same num-
ber of healthy donors (HD). The statistical analysis was performed using
the Student t test: *p b 0.01; **p b 0.001; ***p b 0.0001. Average values
were expressed as mean plus or minus the standard error (SD).
2. Results
2.1. Expression of Different CD45 Isoforms in Patients With Hematological
Malignancies
In healthy donors, NK cells were mainly CD45RA cells with few
CD45RAdim cells, found particularly in immature NK cell subsets.
CD45RARO cells represented between 0 and 0.75% of all NK cells and
belonged exclusively to the fully mature CD56+CD16+ subset (Fig. 1A
top panels and supplemental Table 1). NK cells derived from healthy
donor bone marrows showed equal distribution (Fig. 1B). Blood sam-
ples from patients with multiple myeloma (MM) contained four times
more CD45RAdim cells and between 1 and 20% of CD45RARO cells
(Fig. 1A and supplemental Table 2). AsMM is characterized by accumu-
lation of tumor cells in the bone marrow, we also investigated whether
bone marrow NK cells, which should be in closer contact with tumor
cells, were more activated than circulating NK cells. This was not the
case as the percentage of CD45RAdim and CD45RARO cells was similar
in blood and bone marrow samples (Fig. 1A and supplemental Table 2).Fig. 1. Patients with hematological malignancies and healthy donors have different NK cell su
multiple myeloma (MM) or from bone marrow (bms) of the patient with MM or samples of p
(B cells),−CD3 (T cells, CD3+CD56−) and−CD56 (NK cells, CD56+CD3−), to identify the d
different stage of maturation, and with−CD45RA, and−CD45RO antibodies. Numbers in the
based on CD45RA and RO expression in healthy donors and in patients with hematological c
left (CD45RAdim), upper right (CD45RARO) and bottom right (CD45RAdimRO). The bars sho
blood (left panel) or bone marrow (right panel) samples: *p b 0.01; **p b 0.001; ***p b 0.0001.
BCL, B-cell lymphoma; AML, acute myeloid leukemia; bs, blood samples; bms, bone marrow sSimilar increases in the CD45RAdim and CD45RO populations were
also observed in bone marrow samples from patients with acute mye-
loid leukemia (AML) or in blood samples of patients with B-cell chronic
lymphocyte leukemia (B-CLL) and B-cell lymphoma (BCL) (Fig. 1A and
supplemental Table 3). In summary, the C45RARO cell population was
statistically increased in all analyzed samples from patients with blood
malignancies compared to healthy controls (Fig. 1B and supplemental
Fig. 1). The gating strategy to identify CD45RARO cells is described in
supplemental Fig. 1B).
2.2. Phenotypic Characterization of CD45RARO Population
As indicated in Fig. 1, CD45RARO cells belonged to the CD56+CD16+
subset (Fig. 2A) and mostly express the maturation marker CD57
(Fig. 2B) although CD62L was coexpressed by half of them. The
CD45RARO population contained higher percentage of cells that
expressed KIRs, although it was statistically signiﬁcant only for
CD158e (Fig. 2C and supplemental Fig. 2). The percentage of gran-
zyme B (GzmB)+ cells was similar to other subsets, but the intracel-
lular level of this cytokine was lower (Fig. 2C). This could be due to a
deﬁcient production or a recent degranulation that has emptied the
intracellular stores. CD45RARO cells also expressed similar levels
than CD45RA of another maturation marker the CD161-Killer cell
lectin-like receptor subfamily B, member 1 (KLRB1) or the natural
cytotoxicity receptor (NCR) NKP46 and slightly higher levels of the
activating NKG2D receptor (Fig. 2D and supplemental Fig. 3). How-
ever, they showed lower levels of the CD94 glycoprotein and, prob-
ably, the inhibitory NK receptor NKG2A (Fig. 2D and supplemental
Fig. 3). In summary, CD45RARO cells are fully mature NK cells that
mainly express NK receptors of mature cells.
2.3. Expression of Different CD45 Isoforms in Vivo: Patients With
Cytomegalovirus (CMV)-Reactivation
We next asked whether other conditions that lead to NK cell activa-
tion, such as viral infections, could give rise to a similar phenotype. We
thus analyzed peripheral bloodmononuclear cell (PBMC) samples from
patients with reactivation (CMV+) or not (CMVneg) of CMV infection
following kidney transplantation. CMV reactivation induced an increase
in the total number of NK cells (Fig. 3A). In addition, CMV+ patients
showed an increase in CD56dimCD16dim cells associated with a reduc-
tion of the CD56brigth subsets compared to CMVneg patients (Fig. 3B).
The reason of these changes is not clear to us, but could be due to dif-
ferent factors, such as CMV-induced NK cell maturation (Della Chiesa
et al., 2013), or an effect on the expression of the different NK cell
markers in CMV-infected cells, as previously described for decidual NK
cells (Siewiera et al., 2013). These changes were accompanied by
minor variations in the expression pattern of CD45 isoforms (Fig. 3C).
These results indicate that the expression pattern of CD45 isoforms in
NK cells activated by viral infection or hematological cancers is different.
Speciﬁcally, CD45RARO cells are mainly present in samples from
patients with hematological cancers, whereas they represent a minor
fraction in virus-infected patients.
2.4. Metabolic Characterization of CD45RARO Population
Activated lymphocytes generally increase their size (Zarcone et al.,
1987; Skak et al., 2008) and become highly metabolically active cellsbset proﬁles. A) PBMCs from blood samples (bs) of a healthy donor and of a patient with
atients with other hematological diseases were stained for FACS analysis with anti-CD19
ifferent lymphocyte populations, and also with anti-CD16, to identify NK cell subsets at
quadrants indicate the percentage of cells. B) Percentage of different NK cell populations
ancers. The populations correspond to the quadrants in A: upper left (CD45RA), bottom
w the mean ± SD for each medical condition, Student t-test compare to healthy donor
HD, Healthy donor;MM, multiple myeloma; B-CLL, B-cell chronic lymphocytic leukemia;
amples.
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Thr kinase mammalian target of rapamycin (mTor) probably links the
metabolic shift and the cytoskeletal organization after NK cell activation
(Marcais andWalzer, 2014).We observed a subset of NK cells fromMM
patients that was larger in size (FS) and with high granularity (SS) and
corresponded to CD45RARO cells (Fig. 4A and supplemental Fig. 5C).
This suggested that theywere activated cells that had a highermetabol-
ic activity compared to the other NK subsets. Hence, we activated NK
cells in vitro by incubating them with the Epstein Barr Virus (EBV)
lymphoblastoid cell line PLH. To support NK cell survival we added
low concentrations of two NK cell activating cytokines: IL-2 (100 U/
ml) and IL-15 (5 ng/ml) (Anel et al., 2012). We incubated NK cells for
up to 20 days to reﬂect long-term activation. In agreement with previ-
ous reports (Zarcone et al., 1987; Skak et al., 2008), 10-day activation in-
duced an increase in size (FCS) and granularity (SSC) that was more
relevant at day 20 (supplemental Fig. 4A).
After 3 days of in vitro activation, NK cells started losing CD45RA
(supplemental Fig. 4B). However, it was questionable if a real CD45RARO
population appeared or cells were losing CD45RA whereas gaining
CD45RO. 10 days after initial activation, most cells are CD45RA−
CD45RO+. However, at day 20 a CD45RARO population appeared in the
culture. This was not exclusive of the presence of accessory cells because
long-term activation with cytokines produced a similar pattern (supple-
mental Fig. 4B). In summary, CD45RARO NK cells also exist in vitro after
long activation. Next, we evaluated in vitro activation of patient
CD45RARO population. Three days of cytokine-induced activation in-
duced a strong rearrangement on the expression of CD45 isoforms and
it was impossible to evaluate the faith of individual populations (Supple-
mental Fig. 4C). These results additionally suggested that CD45RARO cells
could change their CD45 phenotype, at least in vitro.
We then assessed the expression of transferrin receptor protein 1
(TfR1 or CD71), which is required for iron delivery from transferrin to
the cells. CD71 expression increases in active metabolic cells be-
cause iron is a cofactor for fundamental biochemical activities,
such as oxygen transport, energy metabolism and DNA synthesis
(Wang and Pantopoulos, 2011). In agreement with the superior
metabolic activity suggested by high FS and SS of CD45RARO cells,
CD71 expression was higher in CD45RO+ cells in both healthy con-
trols and patients with hematological malignancies (Fig. 4B and sup-
plemental Fig. 5A). Moreover, most of these cells also expressed the
proliferation marker Ki-67 (Fig. 4C and supplemental Fig. 5B). In
summary, CD45RARO cells represent a NK subset of highly metabol-
ic cells in proliferation.
CD69 expression increases after NK cell stimulation and is con-
sidered a bona ﬁde marker of NK cell activation (Elpek et al., 2010), in-
cluding ex vivo (Vey et al., 2012). Analysis of CD69 expression in the
different CD45 populations in patients showed that CD45RO+ cells
were mainly CD69+ (Fig. 4D); but not vice versa, as most CD69+ cells
were not CD45RO. The very low amount of CD45RO+ cells in healthy
donors precluded any meaningful analysis of this population.
In healthy donors, CD45RAdim cells were mainly CD69− (Fig. 4E).
CD45RAdim cells were signiﬁcantly increased in patients and many
were also CD69+. However, reduction of CD45RA expressionwas not al-
ways associated with gain of CD69 expression. In fact, patients' samples
were enriched particularly in CD45RAdim CD69− and CD45RA CD69+
and, to a lower extent, in CD45RAdim CD69+ cells. This ﬁnding suggests
that loss of CD45RA and gain of CD69 expression identify two different
physiological processes and that these two populations might have dif-
ferent functions.Fig. 2. The phenotypic characterization of CD45RARO shows that they are fully mature cells. PB
population and thematuration developmentwas revealed by expression of CD56CD16 (A) or CD
5 BCL patients were stained as in Fig. 1 to identify the CD45RARO population and the expressio
against KIRs 158a, b and e, GzmB, the Lectin Like Transcript-1 (LLT1) receptor CD161, the NCRN
CD94.2.5. Functional Characterization of CD45RARO Population
To identify the function of the different NK cell subsets, ﬁrst we
assessed cell degranulation by ex vivo staining of PBMCs with anti-
CD107a antibodies (Fig. 5A). In healthy donors, around 1% NK cells
were CD107a+. Most of these cells were CD45RA, with a small number
of CD45RO+ cells. Remarkably, most CD45RARO and half of CD45RA-
dimRO cells were CD107a+ (Fig. 5B).
NK cells from patients with hematological cancers showed a large
increase in CD107a+ cells (Fig. 5A and supplemental Fig. 6A), particular-
ly among the CD45RO+ subsets, which are speciﬁcally increased in
these patients (Fig. 1). Reduction of CD45RA expression was not associ-
ated with increased degranulation (Fig. 5B). Like in healthy donors, the
CD45RARO and, to a lower extent, CD45RAdimRO fractions contained
mostly cells that had degranulated (Fig. 5B and supplemental Fig. 6B).
The median CD107a-mean ﬂuorescence intensity (MFI) of these two
populations was largely increased compared to CD45RO− populations
(supplemental Fig. 6A). This was not exclusive of circulating NK cells,
because similar results were obtained also for NK cells derived from
bone marrow samples of patients with MM and AML (Fig. 5B and C
upper panels). In contrast, CD45RARO cells showed low GzmB content
(Fig. 2C). Our explanation is that CD45RARO cells had recently
degranulated in vivo.
CD45RARO cells continued to show the higher degranulation rate
after an in vitro analysis using K562 as target cells (Fig. 5C bottom
panels), although other populations signiﬁcantly increased degranula-
tion. Interestingly, the different CD45 NK cell subsets did not change
after the 4-hour in vitro cytotoxic assay (supplemental Fig. 7). This
and the in vitro activation results (supplemental Fig. 4) showed that ex-
pression of CD45RA and CD45RO is stable at short times but can change
after long lasting activation.
2.6. CD45RARO Have Performed Trogocytosis in Vivo
To investigate if CD45RARO cells were performing antitumor activity
in vivo, we investigated if these cells have performed trogocytosis on
tumor targets. Trogocytosis is a process whereby lymphocytes, i.e. NK
cells (Suzuki et al., 2015; Nakamura et al., 2013), gain surfacemolecules
from interacting cells and express them on their own surface and has
been observed in B lymphoblastic leukemia (B ALL) ex vivo (Soma
et al., 2015). We observed that long-time activated NK cells (see sup-
plemental Fig. 4) performed trogocytosis in two AML cell lines (supple-
mental Fig. 8). In fact, NK cells extracted at least two proteins expressed
in AML cells, CD14 and CD33, with considerable efﬁciency. This showed
that human NK cell efﬁciently performed trogocytosis and we investi-
gated if this was the case in vivo. Because in this experiment we studied
markers of other cell types, we used a double labeling to identify NK
cells and gated on CD56+NKP46+ cells. In a BCL patient, we observed
that 14% of the NK cells expressed the BCL marker CD19 in their mem-
brane (Fig. 6A). This value increased to 52% in the CD45RARO popula-
tion and it was much lower in the other populations. NK cells also
gained at lower level expression of the myeloid marker CD14, although
the population was predominantly CD45RAdimRO. However, the NK
cells that stained positive for both CD19 and CD14 were very rare. This
suggested that two different NK cell populations were performing
trogocytosis. The CD45RARO cells were doing it on tumor cells. We
observed the very similar results in another CD19+ disease: B-CLL (sup-
plemental Fig. 9). Next, we used the puriﬁed NK cells (CD56+ selection)
from whole blood of a B-CLL patient and analyzed them with theMCs from a representative BCL patient were stained as in Fig. 1 to identify the CD45RARO
57CD62L (B). Numbers in the quadrant indicate the percentage of cells. C–D) PBMCs from
n of different molecules on the different NK cell subsets was revealed by using antibodies
KP46, the activating receptor NKG2D, the inhibitory receptor NKG2A (D) and themolecule
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Fig. 3. CMV+ patients and patients with hematological cancer have different NK cell subset proﬁles. A) PBMCs from patients with reactivation (CMV+) or not (CMVneg) of CMV infection
following kidney transplantation were puriﬁed as in Fig. 1 and the percentage of NK cells was calculated. B) The abundance (in percentage) of NK cells at different stages of maturation
(CD56 CD16)was analyzed in the samples described in (A). C) The percentage of eachNK cell subsets (CD45 isoforms) is shown. Therewere not any differences between the two groups of
patients. In (B) and (C) bars represent the mean ± SD of at least four individuals for each medical condition.
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pictures of single cells.We labeled cells with NKp46 to formally identify
NK cells together with CD45RA, CD45RO and CD19. Fig. 6B showed that
single cells expressed all markers. Thus, we showed a picture of a
human NK cell that has just performed in vivo trogocytosis in a tumor
cell (see also the graphical abstract).
To exclude that NK cells were not gaining CD19 in all tumors, we in-
vestigated NK cells from an AML patient (Fig. 6B). Around 10% of NK
cells expressed the AML marker CD14 and only 3% expressed CD19,
which was expressed in all NK cell populations. In contrast, 90% of
CD45RARO expressed CD14 showing that they have massively per-
formed trogocytosis in a CD14+ population in AML patients.
Next, we investigated if CD45RARO cells derived from a AML patient
that had performed trogocytosis and gained CD14 expressionwere able
to take CD19 from tumor cells of a BCL patient. Tumor CD19+ cells and
NK cells from the AML patient did not express the same membrane
markers (Fig. 7A). We distinguished BCL cells by CD19 and CD10 stain-
ing and after 16-h cytotoxic assay, we observed that 4% of NK cells form
theAMLpatient gained expression of both CD10 andCD19 (Fig. 7A). The
CD45RARO populationwasmainly stable all through the assay (Fig. 7B).
The population that performed trogocytosis mainly was the CD45RARO
(Fig. 7C). This showed that the CD45RARO population was prompted to
recognize and interact with allogeneic tumor cells. In summary, our
data showed that NK cells performed trogocytosis on tumor cells and
that the CD45RARO population is mainly responsible of this.
3. Discussion
Identiﬁcation of human NK cell populations is important for under-
standing their physiology and for improving their therapeutic use in
the clinic. Altogether our results indicate that CD45RARO cells are fully
mature NK cells (CD56dimCD16+CD57+KIR+CD161+), which areactivated (high size and granularity, CD69+CD71+KI67+NKG2D+)
and that have degranulated (CD107a+ and lowGzmB content) and per-
formed trogocytosis (CD19+ in BCL and B-CLL and CD14+ in AML).
Moreover, they are prompted to perform trogocytosis on different
target cells. These ﬁndings suggest that they are effector cells withmax-
imal cytotoxic activity against cancer cells. It seems that a population of
highly mature NK cells encounters its targets and respond by becoming
effector cells. In addition, we observed that a population of NK cells has
performed trogocytosis in non-tumor, myeloid, cells at least in BCL and
B-CLL patients. It iswell known thatNK cells kill dendritic cells andmac-
rophages in several contexts, but the role here is unknown. Moreover,
the population that has performed it is mainly CD45RAdimRO, a general-
ly minor population.
The large size and granularity of CD45RARO cells could preclude
their observation when standard FCS-SSC parameters for the classical
lymphocyte populations are used. It is essential to understand that acti-
vated lymphocytes increase in size and granularity, which distinguish
them for naïve lymphocytes. This is important for future studies of
CD45RARO NK cells in solid cancers, which could also induce a similar
phenotype becauseNK cell inﬁltration is associatedwith a good progno-
sis in several cancers (Senovilla et al., 2012; Mamessier et al., 2013;
Mamessier et al., 2012). However, our work does not show the irrefut-
able proof that CD45RARO cells are bona-ﬁde NK cells, although all
results point in this direction. Alternative analyses are needed to deﬁn-
itively state the nature of these cells.
Target cell availability is probably maximal for NK cells in blood
borne cancers, hence, we believe that these diseases will show the
highest CD45RARO NK cell numbers; although these cells are unable
to control the disease. Leukemogenesis in mouse is enhanced when
the host immune system is impaired (Garaude et al., 2008; Kaminski
et al., 2012) and more hematological cancer patients present severe
NK cell dysfunctions (Baier et al., 2013). Others and we have shown
Fig. 4. Functional characterization of CD45RARONK cells. A) FS and SS values of the different NK cell subsets (based on the expression of CD45 isoforms) derived from a blood sample of a
patient with MM. B–C) Expression of CD71 and Ki67 in the different NK cell subsets in a representative BCL patient. D–E) Representative graphs showing the expression of CD45RO or
CD45RA versus CD69 in NK cells from blood (bs) or bonemarrow samples (bms) of patients with different blood-borne cancers. Numbers in the quadrant indicate the percentage of cells.
1371E. Krzywinska et al. / EBioMedicine 2 (2015) 1364–1376the requirement of fully functional NK cells to eradicate blood-borne tu-
mors in several mouse models (Karre et al., 1986; van den Broek et al.,
1995; Pardo et al., 2002; Aguilo et al., 2009; Charni et al., 2009; Charni
et al., 2010; Ramírez-Comet et al., 2014). The use of alloreactive NK
cells may represent a new cancer treatment, speciﬁcally for tumors of
hematopoietic origin. Indeed, KIR–KIR ligand incompatibility in the
graft-versus-host (GvH) direction, which is mainly based on NK cell
alloreactivity, improves the outcome after unrelated cord blood stemcell transplantation (UCBT) in the clinic (Willemze et al., 2009; Stern
et al., 2008). Moreover, NK cells: i) are not responsible of GvH disease
(GvHD); ii) can be injected as “differentiated” cells and thus do not
need to survive within the patient's body for a long time; iii) protect
from opportunistic infections (Willemze et al., 2009), probably through
their immunoregulatory effects on B and T cells, macrophages and,
more importantly, polymorphonuclear cells (Bhatnagar et al., 2010).
However, evaluation of NK cell activation in vivo is difﬁcult because
Fig. 5. CD45RARO identiﬁes degranulating NK cells. PBMCs from healthy donors (HD) and patients with different hematological malignancies were puriﬁed as in Fig. 1. A) Number of
CD107a+ cells in eachNK cell subset (CD45RARO expression described in Fig. 1A) permillion of NK cells. Bars represent themean±SD for eachmedical condition; Student t-test compare
to healthy donor samples. B) Percentage of CD107a+ NK cells in the four different subsets. C) Upper panels, Percentage of CD107a+ cells in different NK cell subsets isolated from bone
marrow samples (bms) of patients with MM (shown also the percentage in the corresponding blood sample, bs, for comparison) or AML. Bottom panels, Percentage of CD107a+ cells
in different NK cell subsets after exposure to target K562 tumor cells (in vitro cytotoxicity assay). PBMCs were incubated for 4 h with target K562 tumor cells at the effector:target
ratio of 10:1.
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Fig. 6. CD45RARO cells have performed trogocytosis on tumor cells. PBMCs from patients with BCL (A) or AML (C) were puriﬁed as in Fig. 1 and were stained with different antibodies.
Numbers in the quadrant indicate the percentage of cells. In this experiment, the NK cell population corresponded to CD56+NKP46+ cells. B) Puriﬁed NK cells (CD56+ selection) from
a B-CLL patient have been were stained with NKp46, to formally identify NK cells, together with CD45RA, CD45RO and CD19. They were analyzed with the DEPArray™ System.
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Fig. 7. CD45RARO cells are prompted to perform trogocytosis on allogeneic tumor cells. PBMCs from an AML patient were incubated with puriﬁed tumor cells from a BCL patient (E: (NK
cell):T ratio 0.3:1),which are CD10CD19 for 16 h before stainingwith different antibodies. A) Toppanels identiﬁed the BCL cells, the NK cells before and after cytotoxic assay. In the bottom
panels CD10CD19 expressionwas analyzed in theNK cells described in the top panels. Numbers in the quadrant indicate the percentage of cells. B) CD45RARO expression before and after
cytotoxic assaywas analyzed inNK cells. C) The expression of CD10CD19was analyzed in different NK cell CD45 subsets. The numbers in graphics represent the percentages of cells in the
speciﬁc quadrant.
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tinely been used (Elpek et al., 2010; Vey et al., 2012); though, our results
show that CD69 expression does not imply degranulation, which is be-
lieved to be themost essential component of the NK cell anti-tumor ac-
tivity (Bryceson et al., 2011), or trogocytosis. Conversely, our work
indicates that CD45RO expression identiﬁes degranulating NK cell sub-
sets in patients with hematological malignancies. We believe that efﬁ-
cient antitumor treatments that involve also NK cell activity, such as
monoclonal antibodies against tumor antigens, should also increase
these NK cell populations. Other options for treatment include newchemicals that can be associated with immunotherapy to boost the im-
mune response (Villalba et al., 2014) and that could improve the NK
cell-mediated response (Catalán et al., 2015).
CD45 activity is regulated by dimerization and spontaneous CD45
homodimerization at the plasma membrane inhibits its activity (Xu
and Weiss, 2002). The size of CD45 extracellular domain is inversely
proportional to the extent of CD45 dimerization and thus self-
inhibition (Xu and Weiss, 2002). Larger CD45 isoforms, such as
CD45RA, dimerize less efﬁciently and, accordingly, they should bet-
ter promote TCR signaling than smaller isoforms, such as CD45RO
1375E. Krzywinska et al. / EBioMedicine 2 (2015) 1364–1376(Rhee and Veillette, 2012). However, CD45 activity also depends on
its plasma membrane localization and thus on its extracellular do-
main (Mustelin et al., 2005; Rhee and Veillette, 2012). At least in T
cells, too high CD45 activity leads to dephosphorylation of the acti-
vating residues in Src kinases, whereas too low CD45 activity might
leave phosphorylated the inhibitory residues. Therefore, it is impor-
tant for efﬁcient NK cell activation that CD45 activity remains within
a speciﬁc window (Hermiston et al., 2009) and the amount of specif-
ic CD45 isoforms will regulate the ﬁnal activity. We found that
CD45RARO NK cells show maximal degranulation and trogocytosis,
suggesting that expression of both CD45RA and CD45RO isoforms
might give to NK cells the appropriate level of CD45 activity for efﬁ-
cient signaling to boost cytotoxicity. CD45 is required for full NK cell
cytotoxicity in vivo in mice (Hesslein et al., 2011); however, it is not
required in vitro (Mason et al., 2006; Hesslein et al., 2006;
Huntington et al., 2005). In agreement, we observed that other NK
cell subsets, which express different CD45 isoforms, improved de-
granulation in vitro. This suggests that NK cells depend less of
CD45 expression in vitro than in vivo.
Expression of different CD45 isoforms changes the recognition of
CD45 ligands. For example, the abundance and types of O-glycans on
the different CD45 isoforms regulate the cell sensitivity to galectin-1
(Earl et al., 2010). Galectin-1, which is abundantly produced by tumor
cells, blocks T cell-mediated cytotoxic responses (Ito et al., 2012) and in-
duces apoptosis of thymocytes and T cells (Earl et al., 2010). It is possible
that anti-tumor NK cells are selected based on their resistance to
galectin-1 or to other ligands through expression of CD45RO. Indeed,
as O-glycans bind mainly to CD45 extracellular domain, cells that
express short CD45 isoforms, like CD45RO, will have relatively fewer
O-glycans and thus will be more resistant to galectin-1.
Ex vivo we found very few NK cells that express CD45RO in periph-
eral blood samples from healthy donors. This is surprising, especially if
CD45RO expression identiﬁes memory NK cells, as it has been proposed
(Fu et al., 2011). This ﬁnding suggests that the amount of memory NK
cells might be extremely low in blood or bone marrow samples, or
that CD45RO may not be a marker of memory NK cells. Alternatively,
CD45RO expression in NK cells could have been speciﬁcally lost during
ex vivo sample handling. We think that this is unlikely because NK
cells express slightly higher levels of total CD45 than other lymphocyte
types (data not shown). In fact, we found that CD45RO is mostly associ-
ated with effector NK cells; however, differently fromwhat observed in
most T cell populations, CD45RA down-regulation is not required for NK
cell activation. This suggests that in NK cells the expression of different
CD45 isoforms plays a different role than in T cells.
In summary, we show here that NK cells that recognize tumor cells
are present in all examined patients of hematological cancers. Hence,
NK cells are actively recognizing tumor cells in leukemia patients; but
this seems to be insufﬁcient to eradicate disease. Protocols to enhance
such population should improve patient's prognosis. Finally, the pres-
ence of this population identiﬁes blood-borne cancer patients.4. Financial Support and Acknowledgements
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